The Pathogenesis and Prognostic Factors of Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Real-world regimen.
- Who it may be relevant to
- Registry conditions: Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.
Detailed description
Lymphoma is a highly common malignant tumor in Asia. This study aims to observe and describe the clinical and genetic charateristics of Chinese lymphoma patients, and to explore the relationship between those charateristics and pathogenesis and prognostic factors in the real-world population. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.
Interventions
- Other Real-world regimen
The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
Primary outcome measures
- OS [Time frame: Baseline up to data cut-off (Up to approximately 20 years)]
Secondary outcome measures (1)
- PFS [Time frame: Baseline up to data cut-off (Up to approximately 20 years)]
Eligibility criteria
Inclusion criteria
- Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027.
- Patients with complete diagnostic, treatment and follow-up records.
- Fully comprehension and signature of the informed consent form (ICF) for participation.
Exclusion criteria
- Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period.
- Severe mental illness.
- Patients deemed unsuitable for inclusion by the investigator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Zhongshan Hospital，Fudan University — Shanghai
Identifiers
NCT: NCT06203652 · SHZS-lym-001